Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9NR56
UPID:
MBNL1_HUMAN
Alternative names:
Triplet-expansion RNA-binding protein
Alternative UPACC:
Q9NR56; E9PBW7; O43311; O43797; Q86UV8; Q86UV9; Q96P92; Q96RE3
Background:
Muscleblind-like protein 1, also known as Triplet-expansion RNA-binding protein, plays a pivotal role in pre-mRNA alternative splicing regulation. It can act as both an activator and repressor of splicing on specific targets, influencing key processes in muscle and cardiac function. This protein's ability to bind to specific RNA sequences and structures, including expanded CUG repeat RNA, underscores its importance in cellular mechanisms.
Therapeutic significance:
Muscleblind-like protein 1 is implicated in the pathogenesis of Dystrophia myotonica 1 and Fuchs endothelial corneal dystrophy, 3. Its interaction with pathogenic RNAs highlights a critical role in these diseases, suggesting that targeting MBNL1 could offer novel therapeutic avenues for treating conditions characterized by aberrant splicing.